A novel human monoclonal antibody derived from tumor-infiltrating lymphocytes in lung cancer inhibits cancer cell growth with morphological changes

Anticancer Research

Volumn 25, Issue 6 B, 2005, Pages 3791-3798

  Aoki, Masahiko ^a   Saikawa, Yoshiro ^a   Hosokawa, Saiko ^b   Fukuda, Kazumasa ^a   Kumai, Koichiro ^a   Kubota, Tetsuro ^a   Yoshida, Masashi ^a   Otani, Yoshihide ^a   Kitajima, Masaki ^a  

^a KEIO UNIVERSITY   (Japan)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Hybridoma; Lung cancer; Monoclonal antibody; Tumor infiltrating B lymphocyte

Indexed keywords

ALEMTUZUMAB; CETUXIMAB; GEMTUZUMAB OZOGAMICIN; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN M; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; MONOCLONAL ANTIBODY; RITUXIMAB; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CELL GROWTH; CELL PROLIFERATION; COLON CANCER; CONFOCAL MICROSCOPY; DRUG APPROVAL; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HYBRIDOMA; IMMUNOHISTOCHEMISTRY; LEUKEMIA; LUNG CANCER; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PRIORITY JOURNAL; STOMACH CANCER; TUMOR ASSOCIATED LEUKOCYTE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COLONIC NEOPLASMS; HUMANS; HYBRIDOMAS; IMMUNIZATION, PASSIVE; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, CONFOCAL; PANCREATIC NEOPLASMS; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 27944474691     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Vose BM and Moore M: Human tumor infiltrating lymphocytes: a marker of host response. Semin Hematol 22: 27-40, 1985.
2. Shimokawara I, Imamura M, Yamanaka N, Ishii Y and Kikuchi K: Identification of lymphocyte subpopulations in human breast cancer tissue and its significance: an immunoperoxidase study with anti-human T and B cell sera. Cancer 49: 1456-1464, 1982.
3. Allen C and Hogg N: Elevation of infiltrating mononuclear phagocytes in human colorectal tumors. J Natl Cancer Inst 78: 465-470, 1987.
4. Mantovani A: Tumor-associated macrophages. Curr Opin Immunol 2: 689-692, 1990.
5. Tahara H, Fujio K, Araki Y, Setoguchi K, Misaki Y, Kitamura T and Yamamoto K: Reconstitution of CD8+ T cells by retroviral transfer of the TCR alpha beta-chain genes isolated from a clonally expanded P815-infiltrating lymphocyte. J Immunol 171: 2154-2160, 2003.
6. Kass R, Bellone S, Palmieri M, Cane S, Bignotti E, Tillman RH, Hutchins L, Cannon MJ, Klimberg S and Santin AD: Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells. Breast Cancer Res Treat 80: 275-285, 2003.
7. Whiteside TL and Parmiani G: Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use. Cancer Immunol Immunother 39: 15-21, 1994.
8. Hsiao YW, Liao KW, Hung SW and Chu RMJ: Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta 1 and restores the lymphokine-activated killing activity. J Immunol 172: 1508-1514, 2004.
9. Allan CP, Turtle CJ, Mainwaring PN, Pyke C and Hart DN: The immune response to breast cancer, and the case for DC immunotherapy. Cytotherapy 6: 154-163, 2004.
10. Berger TG, Haendle I, Schrama D, Luftl M, Bauer N, Pedersen Ls LO, Thurner BS, Hohenberger W, Straten PtP, Schuler G and Becker JC: Circulation and homing of melanoma-reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte-derived dendritic cells. Int J Cancer 111: 229-237, 2004.
11. Dudley ME, Wunderlich JR, Shelton TE, Even J and Rosenberg SA: Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26: 332-342, 2003.
12. Gardini A, Ercolani G, Riccobon A, Ravaioli M, Ridolfi L, Flamini E, Ridolfi R, Grazi GL, Cavallari A and Amadori D: Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis. J Surg Oncol 87: 46-52, 2004.
13. von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, Johnk C, Henne-Bruns D, Kremer B and Kalthoff H: Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 7: 925-932, 2001.
14. Carter P: Improving the efficacy of antibody-based cancer therapies. Nature Rev Cancer 1: 118-129, 2001.
15. Weiner LM: An overview of monoclonal antibody therapy of cancer. Semin Oncol 26: 41-50, 1999.
16. Von Mehren M and Weiner LM: Monoclonal antibody-based therapy. Curr Opin Oncol 8: 493-498, 1996.
17. Breedveld FC: Therapeutic monoclonal antibodies. Lancet 355: 735-740, 2000.
18. Glennie MJ and Johnson PW: Clinical trials of antibody therapy. Immunol Today 21: 403-410, 2000.
19. Houghton AN and Scheinberg DA: Monoclonal antibody therapies-A 'constant' threat to cancer. Nat Med 6: 373-374, 2000.
20. Drewe E and Powell RJ: Clininically useful monoclonal antibodies in treatment. J Clin Pathol 55: 81-85, 2002.
21. Clark M: Antibody humanization: a case of the 'Emperor's new clothes'? Immunol Today 21: 397-402, 2000.
22. Zehntner S, Townsend W, Parkes J, Schmidt C, Down M, Bell J, Mulligan R, O'Rourke M, Ellem K and Thomas R: Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy. Pathology 31: 116-122, 1999.
23. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P and Cascinelli N: Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77: 1303-1310, 1996.
24. Halliday GM, Patel A, Hunt MJ, Tefany FJ and Barnetson RS: Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells. World J Surg 19: 352-358, 1995.
25. Hernberg M, Turunen JP, Muhonen T and Pyrhonen S: Tumor-infiltrating lymphocytes in patients with metastatic melanoma receiving chemoimmunotherapy. J Immunother 20: 488-495, 1997.
26. Hale G, Dyer MJ, Clark MR, Phillips JM, Marcus R, Riechmann L, Winter G and Waldmann H: Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 2: 1394-1399, 1988.
27. Baselga J, Norton L, Albanell J, Kim YM and Mendelsohn J: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825-2831, 1998.
28. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T and Levy R: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195, 1997.
29. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J and Levy R: IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15: 3266-3274, 1997.
30. Bernstein ID: Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia 14: 474-475, 2000.
31. Naito K, Takeshita A, Shigeno K, Nakamura S, Fujisawa S, Shinjo K, Yoshida H, Ohnishi K, Mori M, Terakawa S and Ohno R: Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia 14: 1436-1443, 2000.
32. Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X, Johnson D, Apblett R, Kussie P, Bohlen P, Witte L, Hicklin DJ and Ludwig DL: A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth In vivo. Cancer Res 63: 8912-8921, 2003.
33. Vollmers HP, O'Connor R, Muller J, Kirchner T and Muller-Hermelink HK: SC-1, a functional human monoclonal antibody against autologous stomach carcinoma cells. Cancer Res 49: 2471-2476, 1989.
34. Vollmers HP, Dammrich J, Ribbert H, Grassel S, Debus S, Heesemann J and Muller-Hemelink HK: Human monoclonal antibodies from stomach carcinoma patients react with Helicobacter pylori and stimulate stomach cancer cells in vitro. Cancer 74: 1525-1532, 1994.
35. Vollmers HP, Dammrich J, Ribbert H, Wozniak E and Muller-Hermelink HK: Apoptosis of stomach carcinoma cells induced by a human monoclonal antibody. Cancer 76: 550-558, 1995.
36. Vollmers HP, Hensel F, Hermann R, Dammrich J, Wozniak E, Gessner P, Herrmann B, Zimmermann U and Muller-Hermelink HK: Tumor-specific apoptosis by the human monoclonal antibody SC-1: a new therapeutical approach for stomach cancer. Oncol Rep 5: 35-40, 1998.
37. Hensel F, Hermann R, Brandlein S, Krenn V, Schmausser B, Geis S, Muller-Hermelink HK and Vollmers HP: Regulation of the new coexpressed CD55 (decay-accelerating factor) receptor on stomach carcinoma cells involved in antibody SC-1- induced apoptosis. Lab Invest 81: 1553-1563, 2001.
38. Vollmers HP, Zimmermann U, Krenn V, Timmermann W, Illert B, Hensel F, Hermann R, Thiede A, Wilhelm M, Ruckle-Lanz H, Reindl L and Muller-Hermelink HK: Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antibody SC-1: first clinical and histopathological results. Oncol Rep 5: 549-552, 1998.
39. Hermann R, Hensel F, Muller EC, Keppler M, Souto-Carneiro M, Brandlein S, Muller-Hermelink HK and Vollmers HP: Deactivation of regulatory proteins hnRNP A1 and A2 during SC-1 induced apoptosis. Hum Antibodies 10: 83-90, 2001.
40. Hosokawa S, Tagawa T, Niki H, Hirakawa Y, Ito N, Nohga K and Nagaike K: Establishment and evaluation of cancer-specific human monoclonal antibody GAH for targeting chemotherapy using immunoliposomes. Hybridoma Hybridomics 23: 109-120, 2004.
41. Hosokawa S, Tagawa T, Niki H, Hirakawa Y, Nohga K and Nagaike K: Efficacy of immunoliposomes on cancer models in a cell surface-antigen-density-dependent manner. Br J Cancer 89: 1545-1551, 2003.